. 2021 Sep 13;29(10):1575–1579. doi: 10.1002/oby.23251

Table 1.

Vaccine efficacy outcomes in persons with obesity for the three available FDA‐approved SARS‐CoV‐2 vaccines

SARS‐Cov‐2 vaccine	Number of doses required	Percent of participants with obesity	Overall vaccine efficacy % (95% CI)	Vaccine efficacy % (95% CI) in obesity	Notable findings for obesity
Pfizer‐BioNTech BNT162b2	2 (21 days apart)	31.5	95.0 (90.0, 97.9)	95.4 (86.0, 99.1) ^a	Efficacy in younger adults (<64) and older adults (age ≥65) was similar
Moderna mRNA‐1273	2 (28 days apart)	34.5 6.5 with BMI ≥40	94.1 (89.3, 96.8)	95.8 (82.6, 99.0) ^b	None found/reported
Moderna mRNA‐1273	2 (28 days apart)	34.5 6.5 with BMI ≥40	94.1 (89.3, 96.8)	91.2 (32.0, 98.9) ^c	None found/reported
Johnson & Johnson Ad26.CoV2.S	1	28.5	66.9 (59.0, 73.4) ^d	66.8 (54.1, 76.3) ^f	Obesity present in 6/7 deaths in placebo group, no deaths in vaccine group
Johnson & Johnson Ad26.CoV2.S			66.1 (55.0, 74.8) ^e	65.9 (47.8, 78.3) ^g

The Phase 3 trials of these FDA‐approved SARS‐CoV‐2 vaccines had different trial designs and outcome measures in different populations. In addition, vaccines were tested at different periods of time during the pandemic, one trial with a large percentage of a SARS‐CoV‐2 variant (e.g. South Africa B.1.351 in the Johnson & Johnson trial) resulting in the inability to make a direct comparison of the vaccine efficacy in this table.

^{^a}

Participants with obesity (BMI ≥30), 7 days after dose 2, per VRBPAC Briefing Document, December 10, 2020 (19).

^{^b}

Participants with obesity (BMI ≥30), 14 days after dose 2, per VRBPAC Briefing Document, December 17, 2020 (20).

^{^c}

Participants with severe obesity (BMI ≥40), 14 days after dose 2, per VRBPAC Briefing Document, December 17, 2020 (20).

^{^d}

All participants, 14 days after dose 1, per VRBPAC Briefing Document, February 26, 2021 (21).

^{^e}

All participants, 28 days after dose 1, VRBPAC Briefing Document, February 26, 2021 (21).

^{^f}

Participants with obesity (BMI ≥30), 14 days after dose 1, per VRBPAC Briefing Document, February 26, 2021 (21).

^{^g}

Participants with obesity (BMI ≥30), 28 days after dose 1, per VRBPAC Briefing Document, February 26, 2021 (21).

Abbreviation: VRBPAC, Vaccines and Related Biological Products Advisory Committee.